Neurxstem offers a patented human neural organoid platform that replicates the full architecture and cellular composition of the brain, generating high‑precision transcriptomic and metabolomic data with 98–99% reproducibility. The regulator‑grade multi‑omic datasets enable pharmaceutical and biotech companies to identify targets, validate mechanisms of action, and discover biomarkers for CNS diseases and aging, supporting IND‑ready studies and FDA‑aligned diagnostics.
Funding
Funding not disclosed
Founders
Product
Problem
Preclinical research on neurological and age‑related diseases relies on animal models that often fail to predict human molecular responses, leading to costly failures in drug development and delayed diagnostic breakthroughs.
Solution
Neurxstem provides a patented, multi‑regional human neural organoid platform (NNOP™) that reproduces the complete architecture and cellular composition of the human brain, including retina, cortex, midbrain, hindbrain, cerebellum, spinal cord, and blood‑brain barrier. Derived from reprogrammed human skin cells, each organoid generates high‑resolution transcriptomic and metabolomic data with 98–99% reproducibility and strong concordance to clinical tissue profiles. The regulator‑grade, multi‑omic datasets enable early‑stage target identification, mechanism‑of‑action validation, and biomarker discovery for Alzheimer’s, Parkinson’s, migraine, autism, opioid use disorder, and broader aging research. By supplying human‑validated molecular evidence, the platform supports IND‑ready studies, FDA‑aligned diagnostics, and AI models that can predict prodromal disease decades before symptom onset.
Target Audience
Primary customers are pharmaceutical and biotech companies developing CNS therapeutics, diagnostic developers seeking human‑validated biomarkers, and AI health‑tech firms requiring regulator‑grade multi‑omic data for predictive modeling.
Features
- Fully integrated human brain organoid covering all major regions and cell types (neurons, astrocytes, oligodendrocytes, microglia, vascular endothelial cells, BBB)
- Generates >15,000 gene‑expression datapoints per model with matched metabolomic profiles via high‑field NMR
- 98–99% reproducibility across cell lines and replicates, ensuring consistent experimental outcomes
- p < 10⁻¹⁰⁰ transcriptomic concordance with postmortem Alzheimer’s tissue, providing direct human disease relevance
- Patent‑protected platform (issued U.S. patent and extensive provisional portfolio) covering diagnostics, therapeutics, aging models, and AI applications
- Validated by NIH and Department of Defense programs, meeting FDA Modernization Act requirements for human‑relevant preclinical evidence
- Multi‑omic datasets ready for AI training, enabling predictive modeling of prodromal disease trajectories 20–40 years before clinical onset